Ireland Study Notes MSSA Increasing while MRSA Decreasing

Posted in These Categories: News of Hospital Acquired Infections

THE NUMBER of MRSA bloodstream infections reported by hospitals is going down but other types of potentially fatal infections are increasing.

Dr Robert Cunney, who is a specialist with the national Health Protection Surveillance Centre, said while the number of reported MRSA (methicillin resistant staphylococcus aureus) bloodstream infections had dropped to 355 last year from 439 the year before, the number of cases of MSSA (methicillin susceptible staphylococcus aureus) had increased from 864 in 2008 to 954 in 2009.

He said it was not really clear why this was happening, but it may be that one type of bacteria is taking the place of the other as part of some sort of evolution.

While MRSA was associated with higher mortality than MSSA, there was still “a significant risk of death associated with MSSA”.

Cases of the hospital superbug VRE (vancomycin-resistant enterococci) were also increasing in Ireland, he said, adding that Ireland now has one of the highest rates of this infection in Europe.

There is no reliable data on deaths from MRSA in Ireland, the report adds. About 25,000 people pick up infections in Irish hospitals each year, and those who do are seven times more likely to die, the report says

Medizone International, Inc. (Dually Traded: OTCBB/OTCQB: MZEI)
(http://medizoneint.com)

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.

Medizone International, Inc.
Post Office Box 742
Stinson Beach, CA 94970
Telephone: 415-868-0300
Fax: 415-868-2344

This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Tweet This Post

Tags: HAI ireland mrsa mssa